MSH2 and pachyonychia congenita: Moreover, Petrylak et al. [19] analyzed the MSI status of 14 CRPCs: 1 dMMR (MSH2-/MSH6-) CRPC responded to atezolizumab, while another MSI-H PC did not benefit from treatment.